Method for improving transfection efficiency of NK cells
By adding polyglycerin, BX795 and Vectofusin-1 to the NK cell culture medium, the virus invasion conditions was optimized, and the problem of low lentiviral invasion efficiency was solved, efficient NK cell transfection was achieved, and the operation steps were simplified and expanded. The application prospects of CAR-NK cells.
Patent Information
- Application Number
- CN202411076666.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, lentiviruses infect NK cells are less efficient and complex in operation steps, which limits the application of CAR-NK cells.
By adding polyglycerol, BX795 and Vectofusin-1 to the NK cell culture medium, the cell density, interleukin-2 concentration, virus MOI, centrifugal force and liquid change time were adjusted, and the virus infection conditions was optimized, which significantly improved the transformation of NK cells. Dyeing efficiency.
It improves the transfection efficiency of NK cells, simplifies the operation steps, and has achieved widespread application prospects in the preparation of CAR-NK cells.
Smart Images

Figure CN118956970A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedical technology, and in particular, relates to a method for improving NK cell transfection efficiency. Background Art
[0002] Natural Killer Cells (NK cells) are part of the innate immune defense line and an important member of innate lymphocytes, accounting for 1% of the number of immune cells and 2% of the number of lymphocytes. NK cells have natural cytotoxicity and can non-specifically identify and kill virus-infected cells and tumor cells through multiple pathways. This characteristic makes NK cells promising in tumor immunotherapy.
[0003] At present, the FDA-approved immune cell therapy is mainly CAR (Chimeric Antigen Receptor)-T cell therapy, which has achieved significant results in the treatment of specific hematological tumors. However, CAR-T cell therapy is currently limited to the transformation of autologous T cells, and may cause safety issues such as cytokine storms and neurotoxicity. In contrast, the killing effect of NK cells does not depend on MHC molecules and is safer. Therefore, it can significantly reduce costs and improve safety, and has a broader development prospect.
[0004] At present, many studies on CAR-NK cells have entered clinical research. The sources of NK cells are relatively wide, including cord blood, peripheral blood, iPS, and NK92 cell lines. Regarding the preparation of CAR-NK cells, in order to make the exogenous CAR gene express in cells for a longer time, lentiviral vectors have become a commonly used means of exogenous gene delivery in NK cells. It can effectively integrate exogenous genes into the genome of host cells, thereby achieving long-term gene expression. At present, the efficiency of lentivirus infection of NK cells is relatively low, which limits the application of CAR-NK cells. Therefore, it is of great clinical significance to develop a new method that can significantly improve the efficiency of NK cell transfection. Summary of the invention
[0005] In view of this, in order to overcome the technical problems in the above-mentioned prior art that the infection efficiency of lentivirus infecting NK cells is low and the operation steps are relatively complicated, the purpose of the present invention is to provide a method for improving the transfection efficiency of NK cells.
[0006] The present invention explores the types of additives during infection, the cell density during cell infection, the concentration of interleukin-2 in the culture medium, the MOI of the infection virus, the centrifugal force during infection, the centrifugation time, and the time to change the medium after infection, and finally obtains the optimal conditions, which greatly improves the infection efficiency and simplifies the operation steps. The present invention has broad application prospects in the technical field of CAR-NK cell preparation.
[0007] The above-mentioned object of the present invention is achieved through the following technical solutions:
[0008] A first aspect of the present invention provides a method for improving NK cell transfection efficiency.
[0009] Furthermore, the method includes using polybrene, BX795 and Vectofusin-1 to improve the transfection efficiency of NK cells.
[0010] Further, the method comprises the following steps:
[0011] (1) Adding polybrene and BX795 to NK cell culture medium;
[0012] (2) mixing the obtained NK cell culture medium with Vectofusin-1 to obtain a mixed solution;
[0013] (3) Adding a concentrated viral vector solution containing the exogenous gene into the mixed solution, mixing well, and then infecting.
[0014] Furthermore, the cell density of the NK cells in step (1) is 200,000-1,000,000 / mL;
[0015] Optionally, the cell density of the NK cells in step (1) is 200,000 / mL or 1,000,000 / mL;
[0016] Optionally, the concentration of polybrene used in step (1) is (1-20) μg / mL;
[0017] Optionally, the concentration of polybrene used in step (1) is 8 μg / mL;
[0018] Optionally, the concentration of BX795 used in step (1) is (1-20) μM;
[0019] Optionally, the concentration of BX795 used in step (1) is 6 μM;
[0020] Optionally, the culture medium in the NK cell culture medium in step (1) includes α-MEM complete culture medium, RPMI1640 culture medium, Advanced culture medium and / or Opti-MEM culture medium;
[0021] Optionally, the α-MEM complete medium contains fetal bovine serum, horse serum, inositol, β-mercaptoethanol, folic acid, and interleukin-2;
[0022] Optionally, the content of the fetal bovine serum and horse serum is (2-20)% each;
[0023] Optionally, the content of the fetal bovine serum and horse serum is 10% each;
[0024] Optionally, the content of inositol is (0.05-1) mM;
[0025] Optionally, the content of inositol is 0.2 mM;
[0026] Optionally, the content of β-mercaptoethanol is (0.05-1) mM;
[0027] Optionally, the content of β-mercaptoethanol is 0.1 mM;
[0028] Optionally, the folic acid content is (0.005-0.1) mM;
[0029] Optionally, the folic acid content is 0.02 mM;
[0030] Optionally, the content of interleukin-2 is 200-800 IU / mL;
[0031] Optionally, the content of interleukin-2 is 400 IU / mL;
[0032] Optionally, the NK cells include NK-92 cells, PB-NK cells, CB-NK cells and / or stem cell-derived NK cells.
[0033] Furthermore, the dosage of Vectofusin-1 used in step (2) is (5-15) μL;
[0034] Optionally, the dosage of Vectofusin-1 used in step (2) is 10 μL;
[0035] Optionally, the NK cell culture medium in step (2) and the concentrated viral vector solution containing the exogenous gene in step (3) are of equal volume.
[0036] Furthermore, the viral vector containing the exogenous gene in step (3) includes a lentiviral vector, an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a herpes virus vector, a pox virus vector and / or a papilloma virus vector;
[0037] Optionally, the virus infection MOI in step (3) is 20-60;
[0038] Optionally, the virus infection MOI in step (3) is 40;
[0039] Optionally, the infection times in step (3) are 1-2 times;
[0040] Optionally, the infection is performed twice in step (3).
[0041] Furthermore, after the first infestation, the infestation was repeated once the next day;
[0042] Optionally, after the first infection, continue to culture after centrifugation, change the medium after 6-16 hours, and repeat the infection the next day;
[0043] Optionally, the centrifugation conditions are room temperature, 1000-1800g centrifugation for 1h;
[0044] Optionally, the culture condition is culturing at 37°C.
[0045] In some embodiments, the polybrene, also known as hexadimethrine bromide and hexadimethrine bromide, has a CAS number of 28728-55-4. Polybrene is a polycationic polymer. In a specific embodiment of the present invention, the polybrene is purchased from Santa Cruz Company.
[0046] In some embodiments, the BX795 is a potent and selective PDK1 inhibitor with an IC50 of 6 nM, more than 50 times more selectivity than PKA, PKC, c-Kit, and GSK3β, and its CAS number is 702675-74-9. In a specific embodiment of the present invention, the BX795 was purchased from MCE.
[0047] In some embodiments, the Vectofusin-1 is a synthetic, non-cytotoxic cationic polypeptide. In a specific embodiment of the present invention, the Vectofusin-1 was purchased from Miltenyi Company.
[0048] In the present invention, the inventors discovered for the first time through a large number of comparative experiments that the addition of BX795 alone had no enhancing effect on the efficiency of lentivirus infecting NK cells, while the effect of the combination of BX795+polybrene+Vectofusin-1 was significantly better than the combination of polybrene+Vectofusin-1 (positive rate: 82.37% VS 74.78%). That is, the above-mentioned new method for improving the transfection efficiency of NK cells provided by the present invention has achieved technical effects that were unexpected by those skilled in the art.
[0049] In some embodiments, the culture medium in the NK cell culture medium is not particularly limited, including but not limited to: α-MEM complete medium, RPMI 1640 medium, Advanced medium, XVIVO 15 medium, AIM-V medium and / or Opti-MEM medium. In a specific embodiment of the present invention, the culture medium is α-MEM complete medium, and the α-MEM complete medium contains 10% each of fetal bovine serum and horse serum, 0.2mM inositol, 0.1mM β-mercaptoethanol, 0.02mM folic acid, and 200-800IU / mL interleukin-2.
[0050] In some embodiments, the viral vector is not particularly limited, including but not limited to: lentiviral vector, adenoviral vector, retroviral vector, adeno-associated viral vector, herpes virus vector, pox virus vector and / or papilloma virus vector. In a specific embodiment of the present invention, the viral vector is a lentiviral vector.
[0051] In some embodiments, the NK cells are not particularly limited, including but not limited to: NK-92 cells, PB-NK cells (NK cells derived from peripheral blood), CB-NK cells (NK cells derived from umbilical cord blood), NK-92MI cells, iPS-derived NK cells and / or stem cell-derived NK cells. In a specific embodiment of the present invention, the NK cells are NK-92 cells.
[0052] In some embodiments, the method further comprises lentivirus packaging. Specifically, the lentivirus packaging comprises the steps of cell plating, plasmid transfection, collecting viral supernatant, etc. The present invention has no particular limitation on the lentivirus packaging process. Those skilled in the art may use conventional lentivirus packaging steps disclosed in the art to package lentivirus.
[0053] The second aspect of the present invention provides a NK cell product prepared by the method described in the first aspect of the present invention;
[0054] Optionally, the product comprises CAR-NK cells.
[0055] In some embodiments, the present invention has no particular limitation on the NK cell products, and any NK cell products capable of expressing exogenous genes prepared by the method described in the first aspect of the present invention are within the protection scope of the present invention, including but not limited to: CAR-NK cells.
[0056] The third aspect of the present invention provides the use of polybrene, BX795 and Vectofusin-1 in combination to improve the transfection efficiency of NK cells;
[0057] Optionally, the polybrene is used at a concentration of (1-20) μg / mL;
[0058] Optionally, the polybrene is used at a concentration of 8 μg / mL;
[0059] Optionally, the BX795 is used at a concentration of (1-20) μM;
[0060] Optionally, the BX795 is used at a concentration of 6 μM;
[0061] Optionally, the dosage of Vectofusin-1 is (5-15) μL;
[0062] Optionally, the dosage of Vectofusin-1 is 10 μL;
[0063] Optionally, the method described in the first aspect of the present invention is used to improve the transfection efficiency of NK cells.
[0064] In the present invention, the inventors have found for the first time through scientific experimental verification that the combination of polybrene, BX795 and Vectofusin-1 can significantly improve the transfection efficiency of NK cells. Therefore, it has broad application prospects in the field of improving the transfection efficiency of NK cells in vitro.
[0065] The fourth aspect of the present invention provides the use of polybrene, BX795 and Vectofusin-1 in combination in the preparation of a transfection enhancing agent for viral vector transfection of NK cells;
[0066] Optionally, the polybrene is used at a concentration of (1-20) μg / mL;
[0067] Optionally, the polybrene is used at a concentration of 8 μg / mL;
[0068] Optionally, the BX795 is used at a concentration of (1-20) μM;
[0069] Optionally, the BX795 is used at a concentration of 6 μM;
[0070] Optionally, the dosage of Vectofusin-1 is (5-15) μL;
[0071] Optionally, the dosage of Vectofusin-1 is 10 μL;
[0072] Optionally, the method described in the first aspect of the present invention is used to improve the transfection efficiency of NK cells.
[0073] In some embodiments, the transfection enhancing agent may also include other substances that can be used to improve and / or assist in improving the transfection efficiency of NK cells.
[0074] The fifth aspect of the present invention provides a composition for improving the transfection efficiency of NK cells.
[0075] Furthermore, the composition comprises the polybrene, BX795 and Vectofusin-1 as described in the third aspect of the present invention or the fourth aspect of the present invention.
[0076] In some embodiments, the composition may further include other substances that can be used to improve and / or assist in improving the NK cell transfection efficiency.
[0077] Compared with the prior art, the present invention has the following beneficial effects:
[0078] (1) The present invention first discovered that BX795 alone had no enhancing effect on the efficiency of lentivirus infection of NK cells, while the effect of the combination of BX795+Polybrene+Vectofusin-1 was significantly better than the combination of Polybrene+Vectofusin-1 (positive rate: 82.37% VS 74.78%). That is, the new method for improving the transfection efficiency of NK cells provided by the present invention achieved technical effects that were unexpected by those skilled in the art.
[0079] (2) The present invention provides a large number of optional schemes for lentivirus infection of NK cells through a series of comparative experiments, and illustrates the effects of different additives on the efficiency of lentivirus infection of NK cells. These schemes can achieve good infection effects. Among these schemes, the present invention has found two optimal schemes:
[0080] Scheme 1: Cell density is 200,000 / mL, infection is performed twice, the cells are plated on the same day, centrifuged at 1000g, and the medium is changed after 6 hours. This scheme requires less virus and fewer cells, and can maintain a higher positive rate.
[0081] Scheme 2: Cell density is 1 million / mL, infection is performed twice, plating is performed on the same day, centrifugation is performed at 1800g, and medium is replaced after 16 hours. This scheme has the best infection effect, with a larger proportion of strongly positive cells, but it requires a larger amount of virus and cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1 The results of flow cytometry detection of GFP positive rate 3 days after lentivirus infection of NK92 cells under different treatment conditions;
[0083] Figure 2 The results of flow cytometry for GFP positivity on different days for the 4th and 9th schemes in Table 9 are shown;
[0084] Figure 3The results of flow cytometry detection of GFP positivity on different days for the 7th and 8th schemes in Table 9 are shown. DETAILED DESCRIPTION
[0085] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and cannot be understood as limiting the present invention. It can be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents.
[0086] The reagents and raw materials used in the present invention are easily obtained by ordinary technicians in the field and can be obtained from commercial channels unless otherwise specified. The experimental methods in the present invention that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. In particular, the following examples are only used to illustrate the present invention and should not limit the scope of the present invention in any way.
[0087] Embodiment 1 Technical solution of the present invention
[0088] 1. Lentivirus packaging
[0089] (1) Cell plating: 20 million HEK293T cells were inoculated into a T175 flask and plasmid transfection was performed the next morning;
[0090] (2) Plasmid transfection: Mix 45 μL of PEI (160 μg in total, purchased from Polysciences) with 750 μL of opti-MEM basal culture medium (purchased from Thermo); mix 30 μg of lentiviral plasmid pLenti-GFP carrying fluorescent protein, 12 μg of packaging plasmid PMD2.G, and 18 μg of packaging plasmid PSPAX2 with 750 μL of opti-MEM basal culture medium, add the PEI mixture to the plasmid mixture, pipette to mix, and incubate at room temperature for 18 min; add the plasmid and PEI mixture to the cells;
[0091] (3) After 6 h, the culture medium was replaced with DMEM complete culture medium (purchased from Thermo Company);
[0092] (4) Collect the viral supernatant at 48h and 72h after the transfection solution change. The collected viral supernatant needs to be filtered with a 0.45μm filter (purchased from Pall) in time. Add 7.5mL of 5X PEG-8000 virus concentrate (PEG8000 purchased from Sigma, sodium chloride purchased from Aladdin) to every 30mL of viral supernatant. Mix once every 20-30min for a total of 3 times.
[0093] (5) Place at 4°C overnight, centrifuge at 4°C, 5000 g, for 40 min; then centrifuge horizontally at 4000 rpm for 10 min;
[0094] (6) Discard the supernatant and add 500 μL of serum-free α-MEM basal medium (purchased from Thermo) to the precipitate for resuspending. After resuspending, keep 20 μL for subsequent titer detection. Divide the remaining 1 / 3 into one tube and 2 / 3 into another tube. The one used for titer detection is stored at 4°C (within one week). The other viruses are quickly frozen in liquid nitrogen and stored in a -80 refrigerator.
[0095] 2. Lentivirus infection
[0096] (1) NK92 cells were cultured with α-MEM complete medium. On the day of NK92 cell passage, 1 mL of 200,000 cells / mL was taken into a 12-well plate, and polybrene (Polybrene, purchased from Santa Cruz) with a final concentration of 8 μg / mL and BX795 (purchased from MCE) with a final concentration of 6 μM were added thereto to obtain NK92 cell culture medium;
[0097] The composition of α-MEM complete medium includes 10% each of fetal bovine serum and horse serum, 0.2mM inositol, 0.1mM β-mercaptoethanol, 0.02mM folic acid, and 400IU / mL interleukin-2;
[0098] (2) Mix the NK92 cell culture medium with 10 μL of Vectofusin-1 in an equal volume to the virus concentrate to obtain a mixed solution, then add an equal volume of the virus concentrate to the mixed solution, flick to mix, and then add to the original wells of the 12-well plate in step (1);
[0099] (3) Centrifuge at 1000 g for 1 h at room temperature and incubate at 37°C;
[0100] (4) Replace with fresh culture medium after 6 h;
[0101] (5) Repeat the infection on the second day;
[0102] (6) After 72 hours, the infection efficiency was detected by flow cytometry.
[0103] Under this technical solution, the efficiency of GFP lentivirus infecting NK92 is as high as 82%.
[0104] Example 2 Exploration of cell density, interleukin-2 (IL-2) concentration and virus infection multiplicity (MOI) conditions
[0105] 1. Experimental Materials
[0106] NK92 cells, interleukin-2 (purchased from Shuanglu Pharmaceutical), GFP lentivirus concentrate, Polybrene, immune pathway inhibitor BX795, polypeptide Vectofusin-1, α-MEM complete medium (containing 10% each of fetal bovine serum (purchased from Lanzhou Minhai Biological) and horse serum (purchased from Hyclone), 0.2mM inositol (purchased from Sigma), 0.1mM β-mercaptoethanol (purchased from Sigma) + 0.02mM folic acid (purchased from Sigma), interleukin-2 was added before use), 12-well plates (purchased from Thermo), horizontal plate centrifuge (Xiangyi Company), carbon dioxide cell culture incubator (ESCO Company), and flow analyzer (Guava Company).
[0107] 2. Experimental methods
[0108] We initially set the common concentrations of each reagent as the initial test concentration, Polybrene concentration was 8μg / mL, BX795 concentration was 6μM, and Vectofusin-1 concentration was 10μg / mL. By setting the cell density to 200,000, 400,000, and 800,000 / mL, the interleukin-2 concentration to 200, 400, and 800 IU / mL, and the virus infection MOI to 20, 40, and 60, we obtained 9 experimental groups as shown in Table 1 through orthogonal experimental design.
[0109] Table 1 Orthogonal experimental design groups: variables are interleukin-2 concentration, cell density and virus infection multiplicity, and each variable is set to 3 gradients
[0110] Group Cell density / mL Interleukin-2 concentration MOI 1 2.00E+05 200 20 2 2.00E+05 400 60 3 2.00E+05 800 40 4 4.00E+05 200 60 5 4.00E+05 400 40 6 4.00E+05 800 20 7 8.00E+05 200 40 8 8.00E+05 400 20 9 8.00E+05 800 60
[0111] 3. Experimental results
[0112] The results of the orthogonal experiment are shown in Table 2. The results obtained by analyzing the above results using orthogonal software are shown in Table 3. The orthogonal result analysis shows that cell density significantly affects the final positive rate, 200,000 / mL is the optimal cell density, while interleukin-2 concentration and virus infection multiplicity have no significant effect on the positive rate (the p value in the figure represents the significance of the effect, p value greater than 0.05 is not significant, and less than 0.05 represents a significant effect). Combined with the positive rate in the 9 groups of data in the experiment and the previous culture conditions, we determined that the next interleukin-2 concentration is 400IU / mL and the virus infection MOI is 40.
[0113] Table 2 Orthogonal experiment results
[0114] Group Cell density / mL Interleukin-2 concentration MOI Positive rate / % 1 2.00E+05 200 20 63.24 2 2.00E+05 400 60 64.76 3 2.00E+05 800 40 81.97 4 4.00E+05 200 60 65.27 5 4.00E+05 400 40 59.74 6 4.00E+05 800 20 57.22 7 8.00E+05 200 40 54.50 8 8.00E+05 400 20 55.63 9 8.00E+05 800 60 55.44
[0115] Table 3 Analysis results using orthogonal software
[0116]
[0117] Example 3: Exploration of additive combinations that affect the infection efficiency of lentivirus
[0118] 1. Experimental Materials
[0119] NK92 cells, interleukin-2, GFP lentivirus concentrate, Polybrene, immune pathway inhibitor BX795, cGAS inhibitor RU.521 (purchased from MCE), polypeptide Vectofusin-1, α-MEM complete medium (containing 10% each of fetal bovine serum and horse serum, 0.2mM inositol, 0.1mM β-mercaptoethanol + 0.02mM folic acid, interleukin-2 added immediately before use), 12-well plates, horizontal plate centrifuge, carbon dioxide cell culture incubator, and flow cytometry analyzer.
[0120] 2. Experimental methods
[0121] We initially set the common concentrations of each reagent as the initial test concentrations, Polybrene concentrations of 8μg / mL, BX795 concentrations of 6μM, RU.521 concentrations of 1μM, and Vectofusin-1 concentrations of 10μg / mL. By setting the cell density to 200,000 / mL, the interleukin-2 concentration to 400IU / mL, and the virus infection MOI to 40, we designed 7 experimental groups as shown in Table 4.
[0122] Table 4 Experimental design of different additive combinations when lentivirus infects NK92 cells. The additives mainly include polybrene, immune pathway inhibitor BX795, cGAS inhibitor RU.521, peptide
[0123] Vectofusin-1
[0124] Group Polybrene BX795 RU.521 Vectofusin-1 1 + + 2 + + 3 + + 4 + + + 5 + + + 6 + + + 7 + + + +
[0125] 3. Experimental results
[0126] The experimental results are shown in Table 5. The above results indicate that the combination of Polybrene, immune pathway inhibitor BX795, and peptide Vectofusin-1 can achieve the highest efficiency of lentiviral infection of NK92; the combination of the two inhibitors cannot achieve further good results, and when used in combination with the other two, the effect of BX795 is better than that of RU.521.
[0127] Table 5 Experimental results of different additive combinations when lentivirus infected NK92 cells
[0128]
[0129]
[0130] Example 4 Effect of a single additive on the infection efficiency of lentivirus
[0131] 1. Experimental Materials
[0132] NK92 cells, interleukin-2, GFP lentivirus concentrate, Polybrene, immune pathway inhibitor BX795, cGAS inhibitor RU.521, polypeptide Vectofusin-1, α-MEM complete medium (containing 10% each of fetal bovine serum and horse serum, 0.2mM inositol, 0.1mM β-mercaptoethanol + 0.02mM folic acid, interleukin-2 added immediately before use), 12-well plates, horizontal plate centrifuge, carbon dioxide cell culture incubator, flow cytometer.
[0133] 2. Experimental methods
[0134] We initially set the common concentrations of each reagent as the initial test concentrations, Polybrene concentrations of 8μg / mL, BX795 concentrations of 6μM, and Vectofusin-1 concentrations of 10μg / mL. By setting the cell density to 200,000 / mL, interleukin-2 concentration to 400IU / mL, and virus infection MOI to 40, we designed five experimental groups as shown in Table 6.
[0135] Table 6 Experimental design of adding each additive combination when lentivirus infects NK92 cells. The additives mainly include Polybrene, immune pathway inhibitor BX795, cGAS inhibitor RU.521, peptide
[0136] Vectofusin-1
[0137] Group Polybrene BX795 Vectofusin-1 1 2 + 3 + 4 + 5 + + +
[0138] 3. Experimental results
[0139] The experimental results are shown in Table 7. The above results indicate that both Polybrene and Vectofusin-1 can enhance the efficiency of lentivirus infection of NK92, and BX795 alone has no significant effect on the efficiency of lentivirus infection of NK92; unexpectedly, we found that Polybrene helps maintain the positive rate.
[0140] Table 7 Experimental results of adding each additive combination alone when lentivirus infected NK92. Adding Polybrene and Vectofusin-1 alone enhanced the efficiency of lentivirus infection of NK92, while adding BX795 alone had no enhancing effect. Adding all three together was still the optimal group.
[0141] Group Polybrene BX795 Vectofusin-1 Positive rate% 1 65.39 2 + 73.95 3 + 65.20 4 + 73.79 5 + + 74.78 6 + + + 82.37
[0142] In addition, the flow cytometry analysis diagram in the experiment is as follows Figure 1 As shown by Figure 1 It can be seen that BX795 alone causes great damage to cells, resulting in a large number of cell deaths, and subsequent experiments cannot be carried out. If Polybrene is added at the same time, the cytotoxic effect of BX795 can be reduced, and cells can grow normally; and the combination of Polybrene and BX795 can better maintain the positive rate. That is, BX795 alone has no enhancement effect, while the effect of the combination of BX795+Polybrene+Vectofusin-1 is significantly better than the combination of Polybrene+Vectofusin-1 (positive rate: 82.37% VS 74.78%), which is a technical effect that was unexpected by those skilled in the art.
[0143] Example 5 Effects of other conditions (infection times, centrifugal force, fluid replacement time, cell plating time, cell density) on the efficiency of lentivirus infection of NK92 cells
[0144] 1. Experimental Materials
[0145] NK92 cells, interleukin-2, GFP lentivirus concentrate, Polybrene, immune pathway inhibitor BX795, polypeptide Vectofusin-1, α-MEM complete medium (containing 10% each of fetal bovine serum and horse serum, 0.2mM inositol, 0.1mM β-mercaptoethanol + 0.02mM folic acid, interleukin-2 added immediately before use), 12-well plates, horizontal plate centrifuge, carbon dioxide cell culture incubator, flow cytometer.
[0146] 2. Experimental methods
[0147] We initially set the common concentrations of each reagent as the initial test concentration, Polybrene concentration was 8μg / mL, BX795 concentration was 6μM, and Vectofusin-1 concentration was 10μg / mL. By setting the cell density to 200,000 / mL, interleukin-2 concentration to 400IU / mL, and virus infection MOI to 40, we designed 9 experimental groups as shown in Table 8.
[0148] Table 8 Tests the effects of other conditions on the efficiency of lentiviral infection of NK92 cells, including reducing the number of infection times, changing the centrifugal force, changing the time of changing the medium after centrifugation, whether to plate cells one day in advance, and changing the cell density
[0149] Number of infections Cell density / mL Centrifugal force × g Fluid replacement time / h Do you lay the boards one day in advance? 1 2 2.00E+05 1000 6 yes 2 2 4.00E+05 1000 6 yes 3 1 2.00E+05 1000 6 no 4 2 2.00E+05 1000 6 no 5 2 1.00E+06 1000 6 no 6 2 2.00E+05 1800 6 no 7 2 2.00E+05 1000 16 no 8 2 2.00E+05 1800 16 no 9 2 1.00E+06 1800 16 no
[0150] 3. Experimental results
[0151] The experimental results are shown in Table 9. The above results show that the positive rate is the highest on Day 3 under the conditions of cell density of 1 million / mL, infection twice, plating on the same day, centrifugation at 1800g, and changing the medium after 16h; while the positive rate is the highest on Day 5 under the conditions of cell density of 200,000 / mL, infection twice, plating on the same day, centrifugation at 1000g, and changing the medium after 6h. At the same time, plating in advance reduces the efficiency of lentivirus infection of NK92; under the condition of 1000g centrifugation, increasing the cell density reduces the efficiency of lentivirus infection of NK92; the lentivirus infection efficiency is low after one infection, about 61.5%, and the subsequent positive rate decreases rapidly.
[0152] Table 9 Test results of the effects of other conditions on the efficiency of lentivirus infection of NK92 cells. It can be seen from the table that the positive rate was highest on Day 3 under the conditions of cell density of 1 million / mL, infection twice, plating on the same day, centrifugation at 1800g, and changing the medium after 16 hours; while the positive rate was highest on Day 5 under the conditions of cell density of 200,000 / mL, infection twice, plating on the same day, centrifugation at 1000g, and changing the medium after 6 hours.
[0153]
[0154]
[0155] The effects of the two solutions are further compared through flow charts ( Figure 2 ),Depend on Figure 2 It can be seen that the positive rates of the two schemes are similar on the third day, but the proportion of strongly positive cells is greater in scheme 9. Based on this phenomenon, we propose the following assumptions: considering the amount of virus used and the cost, scheme 4 is the most suitable scheme. If scheme 4 cannot achieve the ideal infection effect in the experiment, you can consider using scheme 9 to improve the experimental effect.
[0156] In addition, combined with flow cytometry Figure 3 As a result, when the cell density was 200,000 / mL, if the centrifugal force was 1800g or 1000g and the medium change time was changed to 16h, more cells would die subsequently and no good effect would be obtained.
Claims
1. A method for improving NK cell transfection efficiency, characterized in that: The method includes using polybrene, BX795 and Vectofusin-1 to improve the transfection efficiency of NK cells.
2. The method according to claim 1, characterized in that The method comprises the following steps: (1) Adding polybrene and BX795 to NK cell culture medium; (2) mixing the obtained NK cell culture medium with Vectofusin-1 to obtain a mixed solution; (3) Adding a concentrated viral vector solution containing the exogenous gene into the mixed solution, mixing well, and then infecting.
3. The method according to claim 2, characterized in that The cell density of the NK cells in step (1) is 200,000-1,000,000 / mL; Optionally, the cell density of the NK cells in step (1) is 200,000 / mL or 1,000,000 / mL; Optionally, the concentration of polybrene used in step (1) is (1-20) μg / mL; Optionally, the concentration of polybrene used in step (1) is 8 μg / mL; Optionally, the concentration of BX795 used in step (1) is (1-20) μM; Optionally, the concentration of BX795 used in step (1) is 6 μM; Optionally, the culture medium in the NK cell culture medium in step (1) includes α-MEM complete culture medium, RPMI 1640 culture medium, Advanced culture medium and / or Opti-MEM culture medium; Optionally, the α-MEM complete medium contains fetal bovine serum, horse serum, inositol, β-mercaptoethanol, folic acid, and interleukin-2; Optionally, the content of the fetal bovine serum and horse serum is (2-20)% each; Optionally, the content of the fetal bovine serum and horse serum is 10% each; Optionally, the content of inositol is (0.05-1) mM; Optionally, the content of inositol is 0.2 mM; Optionally, the content of β-mercaptoethanol is (0.05-1) mM; Optionally, the content of β-mercaptoethanol is 0.1 mM; Optionally, the folic acid content is (0.005-0.1) mM; Optionally, the folic acid content is 0.02 mM; Optionally, the content of interleukin-2 is 200-800 IU / mL; Optionally, the content of interleukin-2 is 400 IU / mL; Optionally, the NK cells include NK-92 cells, PB-NK cells, CB-NK cells and / or stem cell-derived NK cells.
4. The method according to claim 2, characterized in that: The dosage of Vectofusin-1 used in step (2) is (5-15) μL; Optionally, the dosage of Vectofusin-1 used in step (2) is 10 μL; Optionally, the NK cell culture medium in step (2) and the concentrated viral vector solution containing the exogenous gene in step (3) are of equal volume.
5. The method according to claim 2, characterized in that: The viral vector containing the exogenous gene in step (3) includes a lentiviral vector, an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a herpes virus vector, a pox virus vector and / or a papilloma virus vector; Optionally, the virus infection MOI in step (3) is 20-60; Optionally, the virus infection MOI in step (3) is 40; Optionally, the infection times in step (3) are 1-2 times; Optionally, the infection is performed twice in step (3).
6. The method according to claim 5, characterized in that After the first infestation, repeat the infestation the next day; Optionally, after the first infection, continue to culture after centrifugation, change the medium after 6-16 hours, and repeat the infection the next day; Optionally, the centrifugation conditions are room temperature, 1000-1800g centrifugation for 1h; Optionally, the culture condition is culturing at 37°C.
7. The NK cell product prepared by the method according to any one of claims 1 to 6; Optionally, the product comprises CAR-NK cells.
8. Application of polybrene, BX795 and Vectofusin-1 in improving the transfection efficiency of NK cells; Optionally, the polybrene is used at a concentration of (1-20) μg / mL; Optionally, the polybrene is used at a concentration of 8 μg / mL; Optionally, the BX795 is used at a concentration of (1-20) μM; Optionally, the BX795 is used at a concentration of 6 μM; Optionally, the dosage of Vectofusin-1 is (5-15) μL; Optionally, the dosage of Vectofusin-1 is 10 μL; Optionally, the transfection efficiency of NK cells is improved by the method described in any one of claims 1-6.
9. Application of polybrene, BX795 and Vectofusin-1 in the preparation of transfection enhancer for viral vector transfection of NK cells; Optionally, the polybrene is used at a concentration of (1-20) μg / mL; Optionally, the polybrene is used at a concentration of 8 μg / mL; Optionally, the BX795 is used at a concentration of (1-20) μM; Optionally, the BX795 is used at a concentration of 6 μM; Optionally, the dosage of Vectofusin-1 is (5-15) μL; Optionally, the dosage of Vectofusin-1 is 10 μL; Optionally, the transfection efficiency of NK cells is improved by the method described in any one of claims 1-6.
10. A composition for improving the transfection efficiency of NK cells, characterized in that: The composition comprises the polybrene as claimed in claim 8 or 9, BX795 and Vectofusin-1.
